AddedRisk Factors
If the Proposed Separation is completed, Corteva may not be able to achieve the full strategic and financial benefits that are expected to result from the Proposed Separation. Following the Proposed Separation, the Seed and Crop Protection businesses will bear the full costs and responsibilities of operating a standalone public company and these dis-synergies may exceed expectations. Moreover, the Seed and Crop Protection businesses will each be smaller, less diversified enterprises, and as a result, the separated companies may be more exposed to industry-specific risks and changing market conditions than Corteva is today. The Proposed Separation also may prompt existing stockholders to divest holdings that no longer align with their investment objectives, potentially affecting the trading value of each company’s common stock following the Proposed Separation. Further, there can be no assurance that the combined value of the common stock of the two companies will be equal to or greater than the value of Corteva’s common stock had the Proposed Separation not occurred.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, while it is expected that Corteva will receive a tax opinion from external counsel to the effect that, among other things, the Proposed Separation will qualify as a tax-free spin-off for U.S. federal income tax purposes, any such opinion is not binding on the U.S. Internal Revenue Service. Accordingly, the U.S. Internal Revenue Service may reach conclusions with respect to the Proposed Separation that are different from the conclusion reached in such opinion. If the Proposed Separation is ultimately determined to be taxable, either Corteva or Corteva’s stockholders could incur significant income tax liabilities.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedRisk Factors
In July 2021, the Biden administration issued an executive order promoting competition in the American economy. The order encouraged further examination and efforts by U.S. regulatory agencies to avoid market concentrations for agricultural inputs, that could challenge the survival of family farms. The executive order also directs the U.S. Secretary of Agriculture to take action to ensure that the intellectual property system, while still incentivizing innovation, does not also unnecessarily reduce competition in seed and other agricultural input markets beyond what is reasonably contemplated by the U.S. Patent Act and propose strategies for addressing those concerns across intellectual property, antitrust, and other relevant laws. While the ultimate impact of the executive order will depend on the actions ultimately resulting from the U.S. regulatory authorities, actions taken by such authorities may increase the regulation and regulatory costs associated with the agriculture industry in the future and restrict the company from pursuing certain growth opportunities, including mergers and acquisitions.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
EIDP has identified a material weakness in its internal control over financial reporting, which could negatively impact the accurate and timely reporting of its results of operations and financial condition.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
As described in the EIDP Management's Report on Internal Control over Financial Reporting within this Annual Report on Form 10-K, the management of EIDP identified a material weakness in its internal control over financial reporting with respect to the appropriate classification of the cash flows covering intercompany activities with Corteva, Inc., which resulted in the restatement of EIDP’s Consolidated Statements of Cash Flows within its financial statements for the year ending 2023 and a material misclassification of the Consolidated Statements of Cash Flows for each of the three subsequent quarters in 2024. While EIDP has developed a remediation plan, it will not be able to conclude whether the remediation of the material weakness was successful until sufficient time has passed to allow management to test the design and operational effectiveness of its enhanced controls. Not fully remediating the material weakness or identifying additional control weaknesses, could result in additional accounting errors or reporting delays that may negatively impact a company’s reputation or reduce its stock price.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
and commercialize certain new products and services, or may result in certain of its products or services being later to market than those of its competitors.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
DuPont is currently disputing with Corteva certain provisions of the Separation Agreement and Tax Matters Agreement.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
As discussed further in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, Corteva is engaging in a dispute resolution process with DuPont related to tax indemnification liabilities and the classification of potential liabilities from certain non-PFAS related disputes. Additional disputes between DuPont and Corteva may arise in the future. If these disputes are not resolved favorably for Corteva, there could be significant impacts to the current carrying value of its indemnification liabilities and cost sharing obligation under the Separation Agreement and the Tax Matters Agreement.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RewordedRisk Factors
While not there is no anticipated required contribution for 2025, 2026, Corteva may make expects to evaluate making discretionary contributions to the principal U.S. pension plan. plan and/or may be required to make contributions in the future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
These restrictions may make it more difficult, time consuming and/or expensive for Corteva to develop and commercialize certain new products and services, or may result in certain of its products or services being later to market than those of its competitors.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, Corteva’s ability to export its products and its sales outside the United States has been, and may continue to be adversely affected by significant changes in trade, tax or other policies, including the risk that other countries may retaliate through retaliating by purchasing less from the United States and the imposition of their own trade restrictions and/or increased tariffs in response to substantial changes to U.S. tariff, trade and tax policies, including those being evaluated by the Trump administration. policies.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Future outbreaks or pandemics could negatively impact customer demand and the company's business, financial condition, and results of operations in numerous ways, including but not limited to increased market volatility that impacts the company's hedging, financial forecasting, and liquidity, including its access to capital markets and delays or modifications to the company's strategic plans and productivity initiatives.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Corteva, furthermore, may These contributions could be required to make significant contributions to its pension plans in the future, which could and adversely affect Corteva’s results of operations, liquidity and financial condition.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, the length of time and the risk associated with the breeding and biotech pipelines are interlinked because both are required as a package for commercial success in markets where
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a competitor were to successfully establish an intermediary platform for distribution of Corteva’s products, it may disrupt Corteva’s distribution model and inhibit Corteva’s ability to provide a complete go-to-market strategy covering the direct, dealer and retail channels. model.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Risks related to the satisfaction of these indemnification obligations and temporarily bearing losses may be increased if DuPont completes the announced spin-off of its DuPont's electronics business spin-off, Qnity Electronics, Inc., or if other divested businesses of Historical DuPont (including Chemours) or Historical Dow do not or are unable to cover their liabilities or satisfy their indemnification obligations.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if the execution of these transactions, investments, or portfolio actions is not successful, it could adversely impact Corteva’s financial condition, cash flows and results of operations. operations and cash flows.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, Corteva has seen an increase in recent years in the number of lawsuits filed by those who identify themselves as public or environmental interest groups seeking to invalidate pesticide product registrations registrations, including those for Enlist One®, and/or challenge the way federal or state governmental entities apply the rules and regulations governing pesticide produce use.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Scrutiny from regulators in the U.S. and abroad may intensify as Corteva’s business presence grows. grows or as industry concentration increases.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
The failure to receive necessary permits or approvals approvals, or the invalidation thereof, could have near- and long-term effects on Corteva’s ability to produce and sell some current and future products.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Defending such claims, even those without merit, could be is time-consuming and expensive.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If DuPont or Dow, as applicable, fails to fulfill its obligations or chooses to not enforce the licensed patents, trade secrets or know-how under the Intellectual Property Cross-License Agreements, the company may not be able to prevent competitors from making, using and selling competitive products and services.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
On October 1, 2025, the company announced its intent to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies, in a transaction that is intended to be a tax-free spin-off for U.S. federal income tax purposes.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
(In millions) Balance at December 31, 2023 $ 501 Remediation payments 1 (58) Net increase in remediation accrual 1 42 Net change, indemnification 2 (7) Balance at December 31, 2024 $ 478 Remediation payments 1 (40) Net increase in remediation accrual 1 67 Net change, indemnification 2 57 Balance at December 31, 2025 3 $ 562
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedMD&A
On March 1, 2023, Corteva completed its acquisitions of all the outstanding equity interests in Stoller Group Inc. (“Stoller”), one of the largest independent companies in the Biologicals industry, and Quorum Vital Investment, S.L. and its affiliates (“Symborg”), an expert in microbiological technologies. The purchase price for Stoller and Symborg was $1,220 million, inclusive of a working capital adjustment, and $370 million, respectively. These acquisitions supplement the Crop Protection business with additional biological tools that complement evolving farming practices. See Note 4 - Business Combinations, to the Consolidated Financial Statements, for additional information.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
In connection with the company’s shift to a global business unit model during 2022, the company assessed its business priorities and operational structure to maximize the customer experience and deliver on growth and earnings potential. As a result of this assessment, the company committed to restructuring actions during the second quarter of 2022, which included the company’s separate announcement to withdraw from Russia ("Russia Exit") (collectively the “2022 Restructuring Actions”). The actions associated with this program are substantially complete.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
prior period. Higher other expense was partially offset by an increase in interest income and the absence of charges incurred in 2022 relating to certain legal matters and losses associated with a previously held equity investment.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
operations, financial condition and cash flows. It is the opinion of the company’s management, however, that the possibility is remote that costs in excess of the range disclosed will have a material impact on the company’s results of operations, financial condition or cash flows. For further discussion, see "Environmental Matters" section on page 58 and Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
The company’s Seed segment currently has certain third-party biotechnology trait license agreements, which require up-front and variable payments subject to the licensor meeting certain conditions. These payments are reflected as other current assets and other assets and are amortized to cost of goods sold as seeds containing the respective trait technology are utilized over the term of the license. The rate of royalty amortization expense recognized is based on the company’s strategic plans which include various assumptions and estimates including product portfolio, market dynamics, farmer preferences, growth rates and projected planted acres. Changes in factors and assumptions included in the strategic plans, including potential changes to the product portfolio in favor of internally developed biotechnology, could impact the rate of recognition of the relevant prepaid royalty.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
At December 31, 2024, the balance of prepaid royalties reflected in other current assets and other assets was approximately $65 million and $160 million, respectively. Through June 30, 2024, the prepaid royalties balance largely related to the non-exclusive license in the United States and Canada for the Monsanto Company's Genuity® Roundup Ready 2 Yield® glyphosate tolerance trait and Roundup Ready 2 Xtend® glyphosate and dicamba tolerance trait for soybeans, which was obtained by the company’s wholly owned subsidiary, Pioneer Hi-Bred International, Inc. (“Pioneer”) (“Roundup Ready 2 License Agreement”).
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
In connection with the departure from these traits in the company's product portfolio in favor of the Enlist E3TM trait platform, beginning January 1, 2020 the company presents and discloses accelerated prepaid royalty amortization expense associated with these prepaid royalties as a component of restructuring and asset related charges - net in the Consolidated Statement of Operations. The accelerated prepaid royalty amortization expense represents the difference between the rate of amortization based on the revised number of units expected to contain the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® trait technology and the per unit cash rate per the Roundup Ready 2 License Agreement. As of December 31, 2024, the Enlist E3TM trait platform has grown to 65 percent of our soybean portfolio. For the year ended December 31, 2024, the company recognized charges of $55 million in restructuring and asset related charges - net in the Consolidated Statement of Operations from non-cash accelerated prepaid royalty amortization expense, which as of the end of the second quarter of 2024 is complete. For further discussion of accelerated prepaid royalty amortization, refer to Note 2 - Summary of Significant Accounting Policies, to the Consolidated Financial Statements.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
Continuing political and social attention to climate change and its impacts has resulted in regulatory and market-based approaches to limit greenhouse gas emissions. The company believes there is a way forward for sustainable climate change mitigation that both enables farmers to meet the demands of a growing population and secures the economic future for the vast majority of the world’s population who depend on agriculture for their livelihoods.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
and mitigate the impact of extreme and volatile weather. The company integrates processes for identifying, assessing and managing climate-related risk into its enterprise risk management program.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RemovedMD&A
While Corteva is working to reduce its role in the emission of greenhouse gasses, it also invests in enabling innovation that can create a more resilient agriculture value chain. The company engages with multiple stakeholders and partners around the globe regarding our innovations and actionable ideas to help safeguard the health and well-being of the planet and its people.
Read it in 10-K Feb 14, 2025 at sec.govopen_in_new
RewordedMD&A
Significant ItemsYear ItemsFor the Year Ended December 31, (In millions) 2025 2024 2023 2022 Restructuring and asset related charges - net $ 146 $ 288 $ 336 $ 363 Bayer resolution 1 610 — — Estimated settlement expense1 expense 2 — 101 204 87 Inventory write-offs2 write-offs 3 — (2) 7 33 Spare parts write-off 3 4 — — 12 — (Gain) loss on sale of business, assets and equity investments2 investments 3,4 (37) (7) (14) (10) Settlement costs associated with the Russia Exit2 — — 8 Seed sale associated with Russia Exit2,4 Exit 3,5 — — (18) (3) Acquisition-related costs5 costs 6 — 6 45 — Employee Retention Credit — — (3) (9) AltEn facility remediation charges 7 37 — 10 33 Insurance proceeds6 proceeds 8 (98) (71) — — Total pre-tax significant items (benefit) charge $ 658 $ 315 $ 579 $ 502 Total tax (benefit) provision impact of significant items7 items 9 (153) (80) (131) (102) Tax only significant item (benefit) charge8 charge 10 77 116 (45) (133) Total significant items (benefit) charge, after tax $ 582 $ 351 $ 403 $ 267
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Operating EBITDAFor the Year Ended December 31, (In millions) 2025 2024 2023 2022 Income (loss) from continuing operations after income taxes (GAAP) $ 1,204 $ 863 $ 941 $ 1,216 Provision for (benefit from) income taxes on continuing operations 484 412 152 210 Income (loss) from continuing operations before income taxes (GAAP) $ 1,688 $ 1,275 $ 1,093 $ 1,426 Depreciation and amortization 1,203 1,227 1,211 1,223 Interest income (136) (132) (283) (124) Interest expense 180 233 233 79 Exchange (gains) losses - net 181 284 397 229 Non-operating (benefits) costs - net 39 174 151 (111) Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges — — — Significant items (benefit) charge 658 315 579 502 Separation costs 35 — — Operating EBITDA (Non-GAAP) $ 3,848 $ 3,376 $ 3,381 $ 3,224
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
These items were partially offset by a $(59) $(55) million deferred tax benefit associated with a change in a legal entity’s U.S. tax characterization, a $(47) million benefit related to U.S. tax credits for increasing research activities and $(32) activities, a $(29) million in benefit related to a capital loss (net of valuation allowance), as well as net tax benefits associated with changes to deferred taxes and in accruals for certain prior year tax positions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Payments Due In (In millions) Total at 2025 2026 2027 and December 31, 2024 2025 beyond Expected cumulative cash requirements for interest payments $ 459 515 $ 100 89 $ 359 426 through maturity Purchase obligations1 2,242 685 1,557 obligations 1 2,022 821 1,201 License agreements2, agreements 2, 3 207 160 46 161 114 Other liabilities2, liabilities 2, 4 274 41 233 276 44 232 Total 5 $ 3,182 2,973 $ 872 1,000 $ 2,310 1,973
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The $232 Restructuring and asset related charges - net were $146 million for the year ended December 31, 2025, which was primarily comprised of a $150 million charge associated with the Crop Protection Operations Strategy Restructuring Program was primarily comprised consisting of $91 $11 million of severance and related benefit costs, $101 $13 million of asset related charges, $10 $60 million in decommissioning and demolition costs and $30 $66 million of contract termination charges.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
COGS was $9,172 million (53 percent of net sales) for the year ended December 31, 2025 compared to $9,529 million (56 percent of net sales) for the year ended December 31, 2024 compared to $9,920 million (58 percent of net sales) for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The company completed the 2021 2022 Share Buyback Plan during the first second quarter of 2023 2025 and repurchased and retired 4,098,000, 17,425,000 7,815,000, 17,909,000 and 5,572,000 10,026,000 shares in the open market and through privately-negotiated transactions for a total cost (excluding excise taxes) of $250 $500 million, $1 billion, billion and $250 $500 million during the years year ended December 31, 2025, 2024 and 2023, 2022 and 2021, respectively.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The company completed the 2021 2022 Share Buyback Plan during the first second quarter of 2023 2025 and repurchased and retired 4,098,000, 17,425,000 7,815,000, 17,909,000 and 5,572,000 10,026,000 shares in the open market and through privately-negotiated transactions for a total cost (excluding excise taxes) of $250 $500 million, $1 billion, billion and $250 $500 million during the years ended December 31, 2025, 2024 and 2023, 2022 and 2021, respectively.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
R&D expense was $1,474 million (8 percent of net sales) for the year ended December 31, 2025 and $1,402 million (8 percent of net sales) for the year ended December 31, 2024 and $1,337 million (8 percent of net sales) for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in R&D expense is in support of the company’s company's long-term growth plans and was primarily driven by an increase in salaries higher employee compensation costs due to higher headcount, variable compensation increases, as well as higher contractor, consulting and contractor costs, partially offset by favorable currency impacts. field, lab and facilities costs.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
SG&A expenses were $3,492 million (20 percent of net sales) for the year ended December 31, 2025 and $3,196 million (19 percent of net sales) for the year ended December 31, 2024 and $3,176 million (18 percent of net sales) for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease was primarily driven by favorable currency effects, ongoing cost and productivity actions, Crop Protection raw material deflation, and a reduction in net royalty expense, partially lower commodity prices and raw material deflation, with a partial offset by an increase in volumes and from higher commodity costs. volumes.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesMD&A
About Approximately 85 percent of total pre-tax environmental operating costs charged to income (loss) from continuing operations for the year ended December 31, 2024 2025 resulted from operations in the U.S.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new